{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:34:54Z","timestamp":1794861294212,"version":"4.9.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Tabelecleucel (tab-cel) is an allogeneic Epstein-Barr virus (EBV)\u2013specific T-cell therapy approved in the European Union for relapsed or refractory (R\/R) EBV-associated posttransplantation lymphoproliferative disorder (PTLD) after rituximab or immunochemotherapy failure. Despite its promise as the first approved option for treating the disorder, real-world evidence remains limited. The aim of this study was to investigate the scope of use and outcomes of tab-cel treatment in the real-world setting across Germany, Austria, and Switzerland. Eleven patients with EBV+ PTLD or other EBV-associated lymphoproliferative disorders (LPD) from 9 academic centers were included for a detailed analysis of baseline characteristics and survival parameters. Of these, 8 patients with PTLD (6 after solid organ transplantation and 2 after allogeneic hematopoietic cell transplantation) and 3 patients with EBV-associated LPDs were treated with a median of 2 cycles of tab-cel (range, 1-3). After a median follow-up of 15.1 months, 6 of 11 (55%) patients remained alive. Initially, 7 of 11 patients (64%) achieved an objective response, with best response occurring at a median of 31 days after the first tab-cel infusion (ie, end of cycle 1). Relapse and progression after tab-cel occurred in 7 of 11 (64%) patients. The estimated median overall survival was 13.4 months (confidence interval, 4.4-14.7), likely because of successful subsequent salvage treatments. Immunotherapy-related adverse events were rare. Tab-cel showed efficacy and low toxicity in patients with R\/R PTLD\/LPD, a vulnerable cohort of immunodeficient or patient who underwent transplantations. These real-world data help elucidate the optimal integration of tab-cel in the management of R\/R PTLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019207","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:02:19Z","timestamp":1774450939000},"page":"4097-4106","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Real-world experience with tabelecleucel within and beyond the approval label"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9361-4467","authenticated-orcid":false,"given":"Kiavasch Mohammad Nejad","family":"Farid","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kocher","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Arnold","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Oncology and Immunology, University Hospital of Gie\u00dfen and Marburg, Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-7464","authenticated-orcid":false,"given":"Josia","family":"Fauser","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-4785","authenticated-orcid":false,"given":"Elisa","family":"Henze","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-2639","authenticated-orcid":false,"given":"Christian","family":"Schultze-Florey","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4223-5316","authenticated-orcid":false,"given":"Carmen Diana","family":"Herling","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[{"name":"6Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"6Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Stadelmann","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"8Department I of Internal Medicine, Medical Faculty at University Hospital of Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[{"name":"8Department I of Internal Medicine, Medical Faculty at University Hospital of Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wehrli","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schnitzler","sequence":"additional","affiliation":[{"name":"11Department of Infectious Diseases and Virology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiraz","family":"Ben-Salah","sequence":"additional","affiliation":[{"name":"12Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"1","key":"2026060911213781800_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41409-023-02127-9","article-title":"Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy","volume":"59","author":"Soci\u00e9","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2026060911213781800_bib2","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2021-147307","article-title":"Clinical outcomes of solid organ transplant patients with Epstein-Barr virus-driven (EBV +) post-transplant lymphoproliferative disorder (PTLD) who fail rituximab plus chemotherapy: a multinational, retrospective chart review study","volume":"138","author":"Dharnidharka","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026060911213781800_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026060911213781800_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"2026060911213781800_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/blood.2019000933","article-title":"Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder","volume":"135","author":"Melani","year":"2020","journal-title":"Blood"},{"issue":"27","key":"2026060911213781800_bib6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026060911213781800_bib7","doi-asserted-by":"crossref","first-page":"e163548","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"2026060911213781800_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/13696998.2024.2354150","article-title":"Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant","volume":"27","author":"Barlev","year":"2024","journal-title":"J Med Econ"},{"issue":"2","key":"2026060911213781800_bib9","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1016\/j.jtct.2023.12.495","article-title":"Clinical experience of tabelecleucel in Epstein\u2013Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) involving the central nervous system","volume":"30","author":"Baiocchi","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026060911213781800_bib10","doi-asserted-by":"crossref","first-page":"1250946","DOI":"10.3389\/fimmu.2023.1250946","article-title":"EBV-induced T-cell responses in EBV-specific and nonspecific cancers","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"2026060911213781800_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020005466","article-title":"EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target","volume":"139","author":"Toner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026060911213781800_bib12","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","article-title":"Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol","volume":"8","author":"Nikiforow","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2026060911213781800_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/biom12030397","article-title":"The Epstein-Barr virus hacks immune checkpoints: evidence and consequences for lymphoproliferative disorders and cancers","volume":"12","author":"Biggi","year":"2022","journal-title":"Biomolecules"},{"issue":"9331","key":"2026060911213781800_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"2026060911213781800_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.2024023847","article-title":"Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial","volume":"144","author":"Chaganti","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2026060911213781800_bib16","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1080\/10428194.2021.1957867","article-title":"A phase I\/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and\/or EBV + lymphomas","volume":"62","author":"Pearse","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2026060911213781800_bib17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026060911213781800_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2026060911213781800_bib19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2014.966242","article-title":"Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders","volume":"56","author":"Vase","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026060911213781800_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fmed.2019.00295","article-title":"Refractory Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes","volume":"6","author":"Mika","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2026060911213781800_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s44313-024-00042-6","article-title":"PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis","volume":"59","author":"Li","year":"2024","journal-title":"Blood Res"},{"key":"2026060911213781800_bib22","author":"Dierickx","year":"30   2  2025"},{"issue":"2","key":"2026060911213781800_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2026060911213781800_bib24","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"2026060911213781800_bib25","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbmt.2013.07.023","article-title":"Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European Group for Blood and Marrow Transplantation report","volume":"19","author":"Siegloch","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026060911213781800_bib26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"2026060911213781800_bib27","article-title":"Tabelecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease: effectiveness and value","author":"Lin","year":"2024","journal-title":"Evidence Report"},{"issue":"suppl 15","key":"2026060911213781800_bib28","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2019.37.15_suppl.2532","article-title":"Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease","volume":"37","author":"Aftab","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026060911213781800_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026060911213781800_bib30","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1182\/blood-2018-99-120133","article-title":"Adoptive therapy with EBV-specific T cells for treatment of CNS EBV post-transplant lymphoproliferative disease arising after hematopoietic stem cell transplant or solid organ transplant","volume":"132","author":"Prockop","year":"2018","journal-title":"Blood"},{"key":"2026060911213781800_bib31","doi-asserted-by":"crossref","first-page":"915986","DOI":"10.3389\/fimmu.2022.915986","article-title":"Case report: cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection","volume":"13","author":"Grze\u015bk","year":"2022","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4097\/2525466\/blooda_adv-2025-019207-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4097\/2525466\/blooda_adv-2025-019207-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:21:51Z","timestamp":1781018511000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/4097\/567389\/Real-world-experience-with-tabelecleucel-within"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019207","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,6,9]]}}}